Latest News

Latest News

Proaxsis

PR8

ProAxsis announces that two of its products, the ProteaseTag® Active NE Immunoassay, and NEATstik®, the first test to enable measurement of active neutrophil elastase at point-of-care, have been selected for inclusion in a major upcoming clinical trial. The BRIDGE study is a 3-year collaborative study, funded by the European Respiratory Society (ERS), in which1000 patients with bronchiectasis across Europe will be recruited and will have multiple assessments including microbiome,proteomics, detailed phenotyping and imaging. The study will explore novel biomarkers and demonstrate what they can add to clinical practice. (Sept 2018)

Read More

PR8

ProAxsis declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for small businesses in Northern Ireland. The awards ceremony took place May 31st in Belfast, and was compered by the UTV newsreader and Northern Ireland correspondent for ITV, Marc Mallett. Over 50 Northern Irish businesses were shortlisted across the 14 award categories. The ProAxsis team were announced as the Innovative Business of the Year by Tina McKenzie, the Chair of the Federation of Small Businesses NI, who sponsored the innovation category. (June 2018)

Read More

PR8

ProAxsis received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative ProteaseTag® technology. The grant is part financed under the European Union’s Investment for Growth and Jobs Programme for Northern Ireland. The project, entitled “The development of ProteaseTags® for deubiquitinases (DUBs): innovative tools for biomarker identification and drug discovery in oncology”, will be over the next 12 months and aims to allow the design and synthesis of peptide-based inhibitors for the DUBs family, implemented followed by an assessment of their incorporation in to prototype activity-based immunoassay formats. (June 2018)

Read More

PR8

ProAxsis ProAxsis is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis has already registered a CE Mark in Europe for its ProteaseTag® Active Neutrophil Elastase Immunoassay as a biomarker of infection and inflammation in patients with chronic respiratory diseases such as bronchiectasis, COPD and cystic fibrosis. The company has now been successful with a recent application to theBioMedical Catalyst competition.

Read More

PR8

ProAxsishosted His Royal Highness, the Duke of York, at their new laboratory facilities within the Concourse III building at Catalyst Inc. Prince Andrew, who is Patron of Catalyst Inc., spent time meeting the team as well as finding out more details about the company’s novel ProteaseTag® technology, which allows for the detection and measurement of active protease biomarkers of disease.

Read More

PR8

ProAxsis and Aptamer Group, the developer of custom affinity ligands to enable the life science industry through its proprietary OptimerTM platform announce a partnership to develop Optimer ligands for ProAxsis’s diagnostic assays. Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsis’s diagnostic assays.(August 2021)

Read More

PR8

ProAxsis announces it has entered into an exclusive licensing agreement with AstraZeneca and will complete the validation and global commercialization of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA test. In AstraZeneca will provide access to intellectual property and technical know-how, and in return will receive an undisclosed royalty fee on future Global net sales of the assay.

Read More

PR8

ProAxsis announced a global licensing agreement with the collaboration of the University of Geneva and the University Hospital of Geneva on a higly novel assay for Cathespin K-dependent periostin cleavage product as a biomarker of bone fragility related to disorders such as osteoporosis.

Read More

PR8

ProAxsis announces a collaborative 12-month project with Northern Ireland Connected Health Innovation Centre (CHIC) based at Ulster University to focus on the development of a quantitative lateral flow device designed to monitor the ongoing clinical status of patients with respiratory diseases such as bronchiectasis, cystic fibrosis and COPD

Read More

PR8

ProAxsis has formed a new partnership with Ulster University, the largest university in Northern Ireland to collaborate on an initial 12-week project with the Eastern Corridor Medical Engineering (ECME) supporting the development of relevant platform technologies

Read More

PR8

ProAxsis announces collaboration with Dr. Gunnar Schroeder and Prof. Cliff Taggart from School of Medicine, Dentistry and Biomedical Science at Queen’s University Belfast as part of the Horizon 2020-funded SPaRK Programme.

Read More

PR8

ProAxsis signs partnership agreement with US based Biotechnology company to develop two key respiratory proteases, utilizing ProteaseTag® technology, a platform technology that allows any protease to be targeted

Read More

PR8

ProAxsis and Queen’s University of Belfast secure a second licensing agreement for exclusive intellectual property rights ProteaseTag® technology

Read More

PR8

ProAxsis and Singapore based Kyberlife announce partnership

Read More

PR8

Stanford University study (Bergener) 2017 NE associated with Pf Bacteriophage with higher levels of P.Aeruginosa

and active NE in CF patients (Sept 2018)

Read More

PR8

Data presentation at ERS

Read More

PR8

Press release from University of Dundee (re bronchiestasis) May2022

Read More